The efficacy and safety of sequential IL-12/23p40 inhibitor and IL-17A inhibitor in the treatment of moderate to severe plaque psoriasis: A multicenter randomized controlled clinical trial (ChiCTR) - Oct 16, 2026 - P=N/A | N=106 | Not yet recruiting | Sponsor: Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of
New trial • Dermatology • Immunology • Psoriasis • IL12A
|